IP Library Granted Patent US 10,111,902
Granted Patent B2
US 10,111,902 · App. 14/629,408 · Granted Oct 30, 2018

Polymers for reversing heparin-based anticoagulation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,111,902
App. No.
14/629,408
Granted
Oct 30, 2018
Kind
B2
Abstract

Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules.

Claims (29)

1. A controlled release delivery device comprising:

a support having a surface;

a heparin binding polymer attached to the surface, the heparin binding polymer comprising:

a first dendritic polyol;

one or more cationic moieties, at least one of the one or more cationic moieties attached to the first dendritic polyol; and

at least one cleavage site; and

heparin bound to the heparin binding polymer, wherein the heparin binding polymer has the structure of Formula (I):

wherein L1, L2, L3, L4 and L5 comprise dendritic polyols.

2. The controlled release delivery device of claim 1 , wherein the surface forms part of a bead.

3. The controlled release delivery device of claim 1 , wherein the surface comprises a flat surface.

4. The controlled release delivery device of claim 1 , wherein the surface forms at least a portion of a cartridge.

5. The controlled release delivery device of claim 1 , wherein the heparin binding polymer is attached to the surface via an acetal bond or a ketal bond.

6. The controlled release delivery device of claim 1 , wherein the heparin binding polymer is attached to the surface via a disulfide bond.

7. The controlled release delivery device of claim 1 , wherein the heparin binding polymer comprises a protective moiety covalently attached to the first dendritic polyol.

8. The controlled release delivery device of claim 1 , wherein the heparin binding polymer comprises a second dendritic polyol, wherein the at least one cleavage site links the first dendritic polyol to the second dendritic polyol.

9. A controlled release delivery device comprising:

a support having a surface;

a heparin binding polymer attached to the surface, the heparin binding polymer comprising:

a first dendritic polyol;

one or more cationic moieties, at least one of the one or more cationic moieties attached to the first dendritic polyol; and

at least one cleavage site; and

heparin bound to the heparin binding polymer, wherein the heparin binding polymer has the structure of Formula (II):

wherein L1, L2, L3, and L4 comprise dendritic polyols.

10. The controlled release delivery device of claim 9 , wherein the surface forms part of a bead.

11. The controlled release delivery device of claim 9 , wherein the surface comprises a flat surface.

12. The controlled release delivery device of claim 9 , wherein the surface forms at least a portion of a cartridge.

13. The controlled release delivery device of claim 9 , wherein the heparin binding polymer is attached to the surface via an acetal bond or a ketal bond.

14. The controlled release delivery device of claim 9 , wherein the heparin binding polymer comprises a protective moiety covalently attached to the first dendritic polyol.

15. The controlled release delivery device of claim 9 , wherein the heparin binding polymer comprises a second dendritic polyol, wherein the at least one cleavage site links the first dendritic polyol to the second dendritic polyol.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Jul 31, 2019
From: CRESTLINE DIRECT FINANCE, L.P.
To: EMPIRE TECHNOLOGY DEVELOPMENT LLC
Reel/Frame 049924/0794 →
SECURITY INTEREST Recorded Jan 29, 2019
From: EMPIRE TECHNOLOGY DEVELOPMENT LLC
To: CRESTLINE DIRECT FINANCE, L.P.
Reel/Frame 048373/0217 →